WO2007002571A3 - Use of an anti c5 complement antibody to treat patients with sickle cell disease - Google Patents
Use of an anti c5 complement antibody to treat patients with sickle cell disease Download PDFInfo
- Publication number
- WO2007002571A3 WO2007002571A3 PCT/US2006/024770 US2006024770W WO2007002571A3 WO 2007002571 A3 WO2007002571 A3 WO 2007002571A3 US 2006024770 W US2006024770 W US 2006024770W WO 2007002571 A3 WO2007002571 A3 WO 2007002571A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sickle cell
- cell disease
- treat patients
- complement antibody
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of treating a sickle cell patient with an anti C5 complement antibody is disclosed. Treatment with said antibody decreases the extent of red blood cell lysis and decreases the consequential clinical sequelae.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69347305P | 2005-06-23 | 2005-06-23 | |
US60/693,473 | 2005-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007002571A2 WO2007002571A2 (en) | 2007-01-04 |
WO2007002571A3 true WO2007002571A3 (en) | 2007-05-03 |
Family
ID=37595940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/024770 WO2007002571A2 (en) | 2005-06-23 | 2006-06-23 | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007002571A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
PT2894165T (en) * | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
IT201600121482A1 (en) * | 2016-11-30 | 2018-05-30 | Univ Degli Studi Di Verona | Factor H for use in the treatment and / or prevention of the formation of heterotrombi in patients with sickle cell disease |
WO2023023220A1 (en) * | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
-
2006
- 2006-06-23 WO PCT/US2006/024770 patent/WO2007002571A2/en active Application Filing
Non-Patent Citations (5)
Title |
---|
HILLMEN P ET AL: "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 6, 5 February 2004 (2004-02-05), pages 552 - 559, XP009057948, ISSN: 1533-4406 * |
MOLD CAROLYN ET AL: "Complement activation during painful crisis in sickle cell anemia", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 76, no. 3 PART 1, 1995, pages 314 - 320, XP008073565, ISSN: 0090-1229 * |
TEST SAMUEL T ET AL: "Defective regulation of complement by the sickle erythrocyte: Evidence for a defect in control of membrane attack complex formation", BLOOD, vol. 83, no. 3, 1994, pages 842 - 852, XP008073566, ISSN: 0006-4971 * |
YAZDANBAKHSH KARINA: "Controlling the complement system for prevention of red cell destruction.", CURRENT OPINION IN HEMATOLOGY. MAR 2005, vol. 12, no. 2, March 2005 (2005-03-01), pages 117 - 122, XP008073571, ISSN: 1065-6251 * |
YAZDANBAKHSH KARINA: "Development of complement therapeutics for inhibition of immune-mediated red cell destruction", TRANSFUSION (MALDEN), vol. 45, no. 2, Suppl. S, August 2005 (2005-08-01), pages 122S - 129S, XP008073567, ISSN: 0041-1132 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007002571A2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007117600A3 (en) | Combination therapy for treating autoimmune diseases | |
WO2014205555A8 (en) | Methods and uses for diagnosis and treatment of prostate cancer | |
NO20074999L (en) | Method and preparation for the treatment of peripheral vascular diseases | |
WO2005107730A3 (en) | Cysteamines for treating complications of hypercholesterolemia and diabetes | |
WO2012083132A3 (en) | Diagnosis and treatments relating to th2 inhibition | |
EA200901211A1 (en) | ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION | |
WO2008150490A3 (en) | Uses and compositions for treatment of psoriasis and crohn's disease | |
WO2007053661A3 (en) | Uses of anti-cd40 antibodies | |
BRPI0818191A2 (en) | methods for the formation of vessels from a placental perfusate cell population and for the treatment of an individual having a heart or vascular disease, disorder, condition or insulin | |
NZ591362A (en) | Multiple-variable dose regimen for treating tnfa-related disorders | |
EA201290883A1 (en) | METHODS OF DIAGNOSTICS AND TREATMENT OF CANCER IN PATIENTS IN WHICH THE RESISTANCE TO FIRST CANCER TREATMENT HAS OR DEVELOPED | |
ATE355852T1 (en) | USE OF BOTULINUM TOXIN FOR THE TREATMENT OF HEART AND Circulatory Diseases | |
DE602006007093D1 (en) | Combination therapy for the treatment of diabetes and related conditions as well as for the treatment of conditions that have been improved in the blood by increasing GLP-1 levels | |
WO2010059969A3 (en) | Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer | |
WO2006009919A3 (en) | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods | |
WO2005020903A3 (en) | Methods of improving the safety of zonisamide therapy | |
WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
WO2010064248A3 (en) | Methods of diagnosing and treating motor neuron diseases | |
WO2007002571A3 (en) | Use of an anti c5 complement antibody to treat patients with sickle cell disease | |
MX2011008439A (en) | Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention. | |
WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
WO2003099105A3 (en) | Diagnosis and treatment of human dormancy syndrome | |
WO2012075222A3 (en) | Method of identifying when a patient undergoing hemodialysis is at increased risk of death | |
WO2007117589A3 (en) | Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06785565 Country of ref document: EP Kind code of ref document: A2 |